Who are RC48-ADC's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Trastuzumab deruxtecan-nxki, DS-8201a.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/rc48-adc.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

RC48-ADC — Competitive Intelligence Brief

RC48-ADC (RC48-ADC) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: HER2-targeted antibody-drug conjugate. Area: Oncology.

phase 3 HER2-targeted antibody-drug conjugate HER2 (human epidermal growth factor receptor 2) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

RC48-ADC (RC48-ADC) — RemeGen Co., Ltd.. RC48-ADC is an antibody-drug conjugate that targets HER2-positive cancer cells by delivering cytotoxic payload directly to tumor cells expressing the HER2 receptor.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
RC48-ADC TARGET	RC48-ADC	RemeGen Co., Ltd.	phase 3	HER2-targeted antibody-drug conjugate	HER2 (human epidermal growth factor receptor 2)
Trastuzumab deruxtecan-nxki	Trastuzumab deruxtecan-nxki	Memorial Sloan Kettering Cancer Center	marketed	HER2-targeted antibody-drug conjugate (ADC)	HER2 (human epidermal growth factor receptor 2)
DS-8201a	DS-8201a	Daiichi Sankyo Co., Ltd.	phase 3	HER2-targeted antibody-drug conjugate	HER2 (human epidermal growth factor receptor 2)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (HER2-targeted antibody-drug conjugate class)

Daiichi Sankyo Co., Ltd. · 1 drug in this class
RemeGen Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). RC48-ADC — Competitive Intelligence Brief. https://druglandscape.com/ci/rc48-adc. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab